Inside GARDP Report [2/6]. In 2024, GARDP achieved big milestones 🚀. From advancing R&D for potential new antibiotic treatments to building critical access pathways, here are 5 ways we made progress last year. 🔗 Learn more in our Annual Report:

We need to improve the global #AMR response for children and newborns!👶. At GARDP, we’re working to develop new treatments for children, especially newborns with sepsis. 📢 Join the #ThisIsBig campaign to ensure children are no longer left behind. 🔗

🚩 A major milestone for global antibiotic access!. GARDP signs an agreement with @drreddys to market zoliflodacin—an investigational first-in-class oral antibiotic for #gonorrhoea in 🇹🇭 Thailand and 🇿🇦 South Africa, where GARDP-led Phase 3 trials showed promising results. 🔗

Grateful to @CCAMP_India for convening the India AMR Innovation Workshop. We shared how contextual innovation paired with global access frameworks can strengthen India’s leadership in the #AMR response. Thanks to all partners advancing science-based solutions where they’re.

Proud to join the ComBac-Africa consortium—a new EU-funded effort to tackle drug-resistant infections in Africa. Led by Saarland University with partners including GARDP, it will strengthen diagnostics & access to antibiotics in sub-Saharan Africa where the highest #AMR

RT @HealthPolicyW: First Newborn Recruited for New Sepsis Study . Neonatal sepsis affects up to three million babies a year globally.….

📢 New Research Publication. We’re pleased to share our latest study published in @PLOSOne, in partnership with @NICD_SA. 🧬 The research examines the epidemiology of Carbapenem-Resistant Enterobacterales (CRE) bloodstream infections in South Africa (2015–2021), using data from.

📊 Inside AntibioticDB. AntibioticDB holds data on 3,000+ antibacterial compounds—from traditional antibiotics to experimental therapies like phages and antivirulence agents🧬🦠📈🧪🔍. With new tools like wildcard search, chemical identifiers, and smarter filters, AntibioticDB is.

Inside GARDP Report [6/6]. Thank you for helping us stand strong against AMR. In 2024, your support helped us push boundaries 🚀 — advancing antibiotic R&D 🔬 and expanding access 🌍 in places often left behind. With your continued support, we can make a BIG difference. 🔗

Inside GARDP Report [5/6]. 💡 Every euro counts in the fight against drug-resistant infections. In 2024, GARDP unlocked an unprecedented €60M to advance antibiotic R&D and access. 📘 🔗 See what this funding helped us achieve in our 2024 Annual Report:

Curious about better clinical study design in infectious diseases?. GARDP is offering 5 attendance grants for Ecraid & ESCMID’s 2025 course in Athens, Greece 🇬🇷 (28–30 Oct). 🌍 Priority will be given to applicants from LMICs and travel costs are not covered. Apply now:

Inside GARDP Report [4/6]. 🔄 GARDP is flipping traditional antibiotic R&D on its head, bringing public and private partners together to develop antibiotics (new and existing) and with access built in from day one. 🔗 Discover how we’re putting public health first — read our

💊 Antibiotics saved Avumile’s life. But other babies have not been as fortunate, as effective antibiotics have not been available. Our clinical trial aims to change this. 📽️ Watch a mother’s story. @CityStG_Health.@AMR_CNPI.@SUhealthsci.@AngelaD_ZA

Can efflux pump inhibitors (EPIs) reshape how we address Gram-negative resistance?. A new Antimicrobial Viewpoint by Marion Flipo & Ruben Hartkoorn discusses the promise and remaining challenges of targeting RND-type efflux pumps to restore antibiotic efficacy. Read it here on

Inside GARDP Report [3/6]. GARDP is uniquely focused on both enhancing the antibiotic R&D pipeline and equitable access. Through strategic partnerships 🤝, global licensing 📄, and targeted R&D🔬, we work to deliver new and existing effective antibiotics — especially in

With the US FDA accepting the application for zoliflodacin, an investigational first-in-class oral antibiotic for #gonorrhoea, we're a step closer to the first new antibiotic in decades. With #AMR rising, this could be a major step in preserving efficacy and expanding equitable

📣 Just 4 days left!. The @MSF_SouthAsia-GARDP #WithoutBordersMediaFellowship on antimicrobial resistance is closing on June 30. If you're a journalist from Afghanistan, Bangladesh, India, Nepal, Pakistan, or Sri Lanka, apply now. 👇. 🔗 #AMR

Inside GARDP Report [1/6]. 📈 Drug-resistant infections are on the rise and "business as usual" won’t reverse the trend. At GARDP, we’re working to turn the global momentum on #AMR into meaningful change by transforming antibiotic R&D and closing the access gap for

🎥 Not sure where to start with AntibioticDB website?. Our short video guide walks you through how to search, filter, and explore 3,000+ antibacterial agents. Fast, clear, and built for researchers, developers, and decision-makers. 🔴▶️ See how it works:.